|
|
Iovance Biotherapeutics inc (NASDAQ: IOVA) |
|
Price: $8.1700
$0.16 
1.998%
|
| Day's High:
| $8.170000076293945
| Week Perf:
| -3.2 %
|
| Day's Low: |
$ 7.66 |
30 Day Perf: |
100.74 % |
| Volume (M): |
12,063,350 |
52 Wk High: |
$ 9.36 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$3.48 |
| Open: |
$7.95 |
52 Wk Low: |
$1.76 |
|
|
| Market Capitalization (Millions $) |
3,419 |
| Shares
Outstanding (Millions) |
419 |
| Employees |
975 |
| Revenues (TTM) (Millions $) |
286 |
| Net Income (TTM) (Millions $) |
-354 |
| Cash Flow (TTM) (Millions $) |
24 |
| Capital Exp. (TTM) (Millions $) |
34 |
Business Description
Iovance Biotherapeutics Inc is a biotechnology company that specializes in developing and commercializing life-saving cell therapies. They focus on the development of tumor-infiltrating lymphocyte (TIL) therapies, which involve the extraction of a patient's own immune cells, expanding and activating them in the lab, and then infusing them back into the patient to target and fight cancer cells.
The company's TIL therapies have shown promising results in clinical trials, particularly in patients with advanced melanoma. Iovance Biotherapeutics aims to provide personalized cancer treatments using TIL therapies as a potential alternative to traditional approaches like chemotherapy.
They have a dedicated team of scientists, researchers, and clinicians who work towards advancing their TIL therapies and expanding their pipeline to target different types of cancer. Additionally, the company collaborates with various academic and industry partners to leverage cutting-edge technology and expertise in their research and development efforts.
Iovance Biotherapeutics Inc operates globally and is committed to improving the lives of cancer patients by delivering innovative cell therapies that harness the power of the immune system to fight cancer.
Company Address: 825 Industrial Road, Suite 100 San Carlos 94070 CA
Company Phone Number: 260-7120 Stock Exchange / Ticker: NASDAQ IOVA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Mon, Sep 22 2025 2:35 AM UTC
SAN CARLOS, Calif. On September 19, 2025, Iovance Biotherapeutics, Inc., a leading biotechnology firm distinguished for its pioneering work in polyclonal tumor infiltrating lymphocyte (TIL) therapies, announced a significant step in its employee engagement strategy. The company, traded under the NASDAQ symbol IOVA, has approved inducement stock options totaling 22,810 shar...
|
| Announcement
Published Sat, May 24 2025 8:39 PM UTC
In the volatile world of pharmaceutical stocks, recent developments surrounding Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have sent ripples of concern through the investment community. The esteemed Rosen Law Firm, a beacon for investor rights, announced the initiation of a class action lawsuit on behalf of those who purchased Iovance securities between May 9, 2024, and Ma...
|
| Announcement
Published Wed, May 21 2025 7:20 PM UTC
A Balanced Perspective on the Legal Proceedings Facing Iovance Biotherapeutics and Its Market Position for CSIMarket.com Context and Legal Developments Iovance Biotherapeutics, Inc. a biotechnology company focused on the development of novel cancer immunotherapies, has been thrust into the spotlight due to legal challenges. On May 21, 2025, Rosen Law Firm, a prominent glob...
|
| Management Announcement
Published Wed, Feb 12 2025 10:30 PM UTC
In an effort to bolster innovation and maintain a competitive edge within the biotechnology sector, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has announced a series of inducement stock grants aimed at attracting and retaining talent in a challenging market environment. Notably, the company recently approved stock options and restricted stock units for the new Chief Commer...
|
| Shares
Published Fri, Feb 21 2025 10:15 PM UTC
In-depth Analysis: Navigating Strategic Growth and Market Realities in BiotechIovance Biotherapeutics, Inc. (NASDAQ: IOVA), a prominent player in the field of biotechnology, continues to forge ahead with its bold commitment to innovation despite facing a challenging market environment. On February 21, 2025, Iovance unveiled its latest strategic maneuver: the approval of indu...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.97 $ |
| Revenues (TTM) |
0.68 $
|
| Cash Flow (TTM) |
0.06 $ |
| Cash |
0.75 $
|
| Book Value |
1.72 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
292,931 |
| Net
Income per Employee (TTM) |
-362,933 |
| Receivable Turnover Ratio (TTM) |
3.93 |
| Inventory Turnover Ratio (TTM) |
3.14 |
| Asset Turnover Ratio (TTM) |
0.31 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.97 $
|
| Revenues (TTM) |
0.68 $ |
| Cash Flow (TTM) |
0.06 $ |
| Cash |
0.75 $
|
| Book Value |
1.72 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Amtagvi |
|
 84.31 % |
of total Revenue |
| Proleukin |
|
15.69 % |
of total Revenue |
| United States |
|
98.66 % |
of total Revenue |
| Rest of world |
|
1.34 % |
of total Revenue |
| Single reportable segment |
|
100 % |
of total Revenue |
| |
On February 27 2025 the Iovance Biotherapeutics Inc provided following guidance
nnIovance Biotherapeutics Inc. Reports Robust Financial Performance and Strategic Updates for Q4 and Full Year 2024nn
On February 27, 2025, Iovance Biotherapeutics Inc. announced its financial results and corporate developments for the fourth quarter and the entirety of 2024, showcasing a strong performance relative to their previous guidance.
In the fourth quarter of 2024, the company generated a total product revenue of $73.7 million. This impressive figure contributed to an annual revenue total of $164.1 million for the fiscal year 2024, landing at the upper threshold of their previously set guidance range of $160 million to $165 million.
Demand for Amtagvi (...
|
|
|
0.21%